Navigation Links
Savient Provides Update on Pegloticase BLA
Date:2/12/2009

ve in the relative benefit to risk profile of the safety and efficacy of this exciting product candidate when used in treating patients who suffer from treatment failure gout," said Paul Hamelin, President.

Key Amendments to the BLA

  • Clearer Data on Cardiovascular Profile. The results of the Company's independent post hoc both blinded and unblinded cardiovascular adjudication provided additional data, which clarified the previous understanding of the cardiovascular profiles of pegloticase. Further details of these findings are outlined below.

  • Updated Immunogenicity Guidance. With additional review and analyses, the Committee and its experts concluded that a clinically important immune response in pegloticase can be detected within the first 4 months through monitoring serum uric acid in normal medical practice patterns. A lack of uric acid response correlates with high levels of antibody production. The Company expects this to enable physicians to more quickly identify patients who should discontinue treatment.

  • Revised REMS Program. The Committee determined the Company's application would be strengthened by revising the Risk Evaluation and Mitigation Strategy (REMS) program. The revised REMS program proposed is based on an Elements To Assure Safe Use (ETASU) program. ETASU is a performance-linked access program for prescribers, infusion sites and patients that will have to enroll in this annual program and be certified in order to prescribe, administer or receive pegloticase. The Company also revised its previously proposed 1,000 patient observational study to be an expanded voluntary registry of up to 3,000 patients. The expanded registry will allow the Company to capture additional information about both the cardiovascular and immunogenicity profiles.

  • '/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. USAID Provides Malaria Assistance to Zimbabwe
3. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. American Dairy Provides Business Update
6. Alfacell Provides ONCONASE(R) NDA Submission Update
7. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
8. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
9. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... , December 24, 2014 ... Report on Global Disposable Syringe Industry of ... its online business intelligence library. ... Disposable Syringe Industry is a professional and ... market.  For overview analysis, the report introduces ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... April 5, 2011 Vista Partners announced today ... (OTCBB: PRWP) ("the Company") and raised its twelve month target ... stated, "The Company stated that it has reached an agreement ... controlled, and blinded Phase III clinical trial of DAVANAT®. We ...
... Companies, Inc. (NYSE: PRX ) announced today that ... Thursday, May 5, 2011 at 9:00 AM ET to review ... financial results on May 5, 2011 before the market opens. ... via the Company,s website at www.parpharm.com .Dial-in InformationDomestic: , ...
Cached Medicine Technology:Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22 2
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... of youth" drug that can delay the effects of aging ... suggests. Seniors received a significant boost to their immune ... pathway linked to aging and immune function, researchers with the ... a version of the drug rapamycin, improved the seniors, immune ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... The American Association for Dental Research (AADR) has ... AADR William B. Clark Fellowship in Clinical Research. This ... Meeting & Exhibition in Washington, DC, March 3, 2010. ... Department of Periodontics, University of Texas, Health Science at ...
... ... children and we are working with our members to develop new tools to keep the ... ... International Consumer Product Health & Safety Organization’s (ICPHSO) CPSC Day in Washington, D.C. on February ...
... radiation may not be necessary for early malignancy, study ... alone offers a reasonable overall level of survival for ... new study suggests. , Traditional treatment regimens for limited ... study, researchers analyzed U.S. National Cancer Institute data on ...
... , ... ... ... ...
... ... vitamin and supplement retailer recently launched a robust health encyclopedia offering health news and ... knowledge and more. , ... Shelby Township, Mich. (PRWEB) February 19, 2010 -- eVitamins™, a leading online retailer ...
... Ecological, physiological similarities provide basis for insights, expert says, ... that dolphins suffer from diseases similar to those found ... on the effects that contaminated water and seafood have ... and their diet includes much of the same seafood ...
Cached Medicine News:Health News:JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts 2Health News:JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts 3Health News:JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:eVitamins Launches New Health Encyclopedia 2Health News:Dolphins May Warn of Health Risks in Humans 2
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
... aerosol contamination, which causes ... PCR. Hydrophobic, nonwicking and ... can pass through these ... contrast to tips with ...
... AvantGard Low Binding 20l Barrier Tips. Low ... DNA and proteins bound to the tip. Most ... which means the focus is on liquid not ... focuses on low binding which reduces the binding ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Medicine Products: